

Sustainability Data Content Index 2023

Contents

SASB Index	2	GRI Content Index	5	Site certifications	11
SASB Standard: Biotechnology & Pharmaceuticals	2	General disclosures	5	Material topics	6

Online resources:

-  [AstraZeneca Sustainability webpages](#): cover additional topics of interest to our stakeholders.
-  [AstraZeneca Sustainability Report](#): presents our approach to sustainability and progress in the reporting period, with data annex for performance measures and targets.
-  [Policies and company standards](#): state our positions and guidance on key topics.
-  [Infographics](#): show our processes and practices.
-  [Annual Report 2023](#): includes how sustainability is integrated across our business model and our risk management.

SASB Index

SASB Standard: Biotechnology & Pharmaceuticals

This is an index to the location of our disclosures that align with the Sustainability Accounting Standards Board (SASB) standard for Biotechnology & Pharmaceuticals (2018). The report provides data from 1 January 2023 to 31 December 2023, unless otherwise stated.

Metric code	Metric	Disclosure Location
Safety of Clinical Trial Participants		
HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	Annual Report 2023, p. 36 Bioethics Policy , pp. 4–7
HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	2023: VAI – 2, OAI – 0 2022: VAI – 1, OAI – 0 2021: VAI – 0, OAI – 0
HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	To the extent we are aware of any material responsive matters, they would have been disclosed as part of our Annual Reports and Form 20-F Information, and quarterly updates thereto.
Access to Medicines		
HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	Sustainability Report 2023; pp. 9-14 2022 Access to Medicines Index Report ; pp. 156–159
HC-BP-240a.1	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	WHO PreQualification approved products
Affordability In Pricing		
HC-BP-240b.1	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	To the extent we are aware of any material responsive matters, they would have been disclosed as part of our Annual Reports and Form 20-F Information, and quarterly updates thereto.
HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	Not reported
HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	Not reported

SASB Index

Metric code	Metric	Disclosure Location
Drug Safety		
HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	FDA Adverse Event Reporting webpage
HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	FDA Adverse Event Reporting webpage
HC-BP-250a.3	Number of recalls issued, total units recalled	Sustainability Report 2023, p. 40
HC-BP-250a.4	Total amount of product accepted for take-back, reuse, or disposal	Not reported
HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	FDA – Inspection Citations FDA – Warning letters
Counterfeit Drugs		
HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	SASB response: Counterfeit drugs
HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	SASB response: Counterfeit drugs
HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	Not reported
Ethical Marketing		
HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	To the extent we are aware of any material responsive matters, they would have been disclosed as part of our Annual Reports and Form 20-F Information, and quarterly updates thereto.
HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	AstraZeneca Global Standard: Promoting our products
Employee Recruitment, Development and Retention		
HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	Annual Report 2023, pp. 44-45
HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others	Sustainability Report 2023, p. 40

SASB Index

Metric code	Metric	Disclosure Location
Supply Chain Management		
HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit programme or equivalent third-party audit programmes for integrity of supply chain and ingredients	We do not use third-party auditing organisations. AstraZeneca has an internal risk based supplier assessment system. In 2023 Global Quality Audit completed 561 internal quality audits of AstraZeneca suppliers and 76 internal quality audits of AstraZeneca sites.
Business Ethics		
HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	To the extent we are aware of any material responsive matters, they would have been disclosed as part of our Annual Reports and Form 20-F Information, and quarterly updates thereto.
HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	AstraZeneca and Global Transparency
Activity Metrics		
HC-BP-000.A	Number of patients treated	Annual Report 2023, pp. 10-11
HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	Our Therapy Areas

GRI Content Index

Statement of use

AstraZeneca has reported the information cited in this GRI content index for the period 1 January 2023–31 December 2023 with reference to the GRI Standards.

GRI 1 used

GRI 1: Foundation 2021

GRI Standard	Disclosure	Location
General Disclosures		
GRI 2: General Disclosures 2021	2-1 Organisational details	Sustainability Report 2023, p. 5 Annual Report 2023, pp. 211–215, 225, 228, back cover
	2-2 Entities included in the organisation's sustainability reporting	Sustainability Report 2023, p. 2 Greenhouse Gas Methodologies 2023 p. 2
	2-3 Reporting period, frequency and contact point	AstraZeneca publishes a Sustainability Report annually, this report describes our approach and progress from 1 January 2023 to 31 December 2023. Questions about the report or reported information can be sent to disclosures@astrazeneca.com
	2-4 Restatements of information	Sustainability Report 2023 pp. 30–40
	2-5 External assurance	Sustainability Report 2023, p. 2
	2-6 Activities, value chain and other business relationships	Sustainability Report 2023, p. 8 Annual Report 2023, pp. 10–11, 40–42
	2-7 Employees	Annual Report 2023, p. 33
	2-8 Workers who are not employees	Not reported
	2-9 Governance structure and composition	Sustainability Report 2023, p. 6 Annual Report 2023, pp. 77–79, 87–88, 90–91
	2-10 Nomination and selection of the highest governance body	Annual Report 2023, pp. 90–91
	2-11 Chair of the highest governance body	Annual Report 2023, pp. 78–79
	2-12 Role of the highest governance body in overseeing the management of impacts	Sustainability Report 2023, p. 6 Annual Report 2023, pp. 46, 81–83, 93, 96 Terms of Reference of the AstraZeneca Sustainability Committee
	2-13 Delegation of responsibility for managing impacts	Sustainability Report 2023, p. 6 Annual Report 2023, pp. 77, 80–83
	2-14 Role of the highest governance body in sustainability reporting	Annual Report 2023, pp. 93, 96 Terms of Reference of the AstraZeneca Sustainability Committee
	2-15 Conflicts of interest	Annual Report 2023, p. 225
	2-16 Communication of critical concerns	Annual Report 2023, pp. 49, 83
	2-17 Collective knowledge of the highest governance body	Sustainability Report 2023, p. 6 Annual Report 2023, pp. 82, 91, 93
	2-18 Evaluation of the performance of the highest governance body	Annual Report 2023, p. 89
	2-19 Remuneration policies	Annual Report 2023, pp. 83, 102–138 Remuneration Policy
	2-20 Process to determine remuneration	Annual Report 2023, pp. 83, 102–138 Remuneration Policy
	2-21 Annual total compensation ratio	Annual Report 2023, p. 124
	2-22 Statement on sustainable development strategy	Sustainability Report 2023, p. 3 Annual Report 2023, pp. 2–4
	2-23 Policy commitments	Sustainability Report 2023, pp. 25–26 Code of Ethics Human Rights Statement
	2-24 Embedding policy commitments	Sustainability Report 2023, pp. 6, 25–28 Annual Report 2023, pp. 46–49 Expectations of Third Parties Code of Ethics Human Rights Statement

GRI Content Index

GRI Standard	Disclosure	Location
GRI 2: General Disclosures 2021	2-25 Processes to remediate negative impacts	Sustainability Report 2023, pp. 16, 17, 19, 22, 26, 28 Annual Report 2023, pp. 46–49 Expectations of Third Parties Code of Ethics Human Rights Statement
	2-26 Mechanisms for seeking advice and raising concerns	Sustainability Report 2023, pp. 25–26 Annual Report 2023, p. 49
	2-27 Compliance with laws and regulations	Sustainability Report 2023, p. 36
	2-28 Membership associations	Sustainability Report 2023, pp. 13, 19, 21, 27 Annual Report 2023, p. 40 Partnerships, alliances and recognition
	2-29 Approach to stakeholder engagement	Sustainability Report 2023, p. 8 Annual Report 2023, pp. 84–86
	2-30 Collective bargaining agreements	Not reported
Material Topics		
GRI 3: Material Topics 2021	3-1 Process to determine material topics	Sustainability Report 2023, p. 7
	3-2 List of material topics	Sustainability Report 2023, p. 7 Annual Report 2023, p. 46
Economic Performance		
GRI 3: Material Topics 2021	3-3 Management of material topics	Annual Report 2023, pp. 51–53 TCFD Statement 2023
GRI 201: Economic Performance 2016	201-2 Financial implications and other risks and opportunities due to climate change	Annual Report 2023, pp. 51–53 TCFD Statement 2023
Indirect Economic Impacts		
GRI 3: Material Topics 2021	3-3 Management of material topics	Sustainability Report 2023, pp. 10–14, 30 Annual Report 2023, p. 47
GRI 203: Indirect Economic Impacts 2016	203-1 Infrastructure investments and services supported	Sustainability Report 2023, pp. 10–14, 30–31 Annual Report 2023, p. 47
	203-2 Significant indirect economic impacts	Sustainability Report 2023, pp. 10–14, 30–31 Annual Report 2023, p. 47
Anti-corruption		
GRI 3: Material Topics 2021	3-3 Management of material topics	Sustainability Report 2023, pp. 25–26, 37 Annual Report 2023, pp. 39, 49, 83 Anti-Bribery & Anti-Corruption Global Standard
GRI 205: Anti-corruption 2016	205-2 Communication and training about anti-corruption policies and procedures	Sustainability Report 2023, p. 37

GRI Content Index

GRI Standard	Disclosure	Location
Materials		
GRI 3: Material Topics 2021	3-3 Management of material topics	Sustainability Report 2023, pp. 16, 20–23, 34–36 Annual Report 2023, p. 48 Raw Materials Responsible Sourcing Framework Biodiversity Position Statement
Energy		
GRI 3: Material Topics 2021	3-3 Management of material topics	Sustainability Report 2023, pp. 16–19, 33 Annual Report 2023, p. 48
GRI 302: Energy 2016	302-1 Energy consumption within the organisation	Sustainability Report 2023, p. 33
	302-3 Energy intensity	Sustainability Report 2023, p. 33
Water and Effluents		
GRI 3: Material Topics 2021	3-3 Management of material topics	Sustainability Report 2023, pp. 16, 20–23, 35 Annual Report 2023, p. 48 Pharmaceuticals in the Environment Statement Water Stewardship Position Statement Biodiversity Position Statement
GRI 303: Water and Effluents 2018	303-1 Interactions with water as a shared resource	Sustainability Report 2023, pp. 22–23 Annual Report 2023, p. 48 Pharmaceuticals in the Environment Statement Water Stewardship Position Statement
	303-2 Management of water discharge-related impacts	Pharmaceuticals in the Environment Statement Water Stewardship Position Statement
	303-3 Water withdrawal	Sustainability Report 2023, p. 35 Sustainability Reporting Criteria
Biodiversity		
GRI 3: Material Topics 2021	3-3 Management of material topics	Sustainability Report 2023, pp. 16, 22–23, 34–36 Annual Report 2023, p. 48 TCFD Statement 2023 Biodiversity Position Statement Bioethics Policy
GRI 304: Biodiversity 2016	304-2 Significant impacts of activities, products and services on biodiversity	Sustainability Report 2023, pp. 22–23 Biodiversity Position Statement

GRI Content Index

GRI Standard	Disclosure	Location
Emissions		
GRI 3: Material Topics 2021	3-3 Management of material topics	Sustainability Report 2023, pp. 16–19, 32–34 Annual Report 2023, pp. 48, 51–53 TCFD Statement 2023
GRI 305: Emissions 2016	305-1 Direct (Scope 1) GHG emissions	Sustainability Report 2023, p. 32
	305-2 Energy indirect (Scope 2) GHG emissions	Sustainability Report 2023, p. 32
	305-3 Other indirect (Scope 3) GHG emissions	Sustainability Report 2023, p. 33
	305-4 GHG emissions intensity	Sustainability Report 2023, pp. 32, 34
	305-7 Nitrogen oxides (NO _x), sulphur oxides (SO _x), and other significant air emissions	Sustainability Report 2023, p. 33
Waste		
GRI 3: Material Topics 2021	3-3 Management of material topics	Sustainability Report 2023, pp. 16, 20–23, 34–36 Annual Report 2023, p. 48
GRI 306: Waste 2020	306-1 Waste generation and significant waste-related impacts	Sustainability Report 2023, p. 22
	306-3 Waste generated	Sustainability Report 2023, pp. 35–36 Sustainability Reporting Criteria
	306-4 Waste diverted from disposal	Sustainability Report 2023, pp. 35–36
	306-5 Waste directed to disposal	Sustainability Report 2023, pp. 35–36
Supplier Environmental Assessment		
GRI 3: Material Topics 2021	3-3 Management of material topics	Sustainability Report 2023, pp. 25-26,38 Annual Report 2023, p. 40 TCFD Statement 2023 Expectations of Third Parties Sustainability Partner Guide and Framework
GRI 308: Supplier Environmental Assessment 2016	308-2 Negative environmental impacts in the supply chain and actions taken	Sustainability Report 2023, p. 38
Employment		
GRI 3: Material Topics 2021	3-3 Management of material topics	Annual Report 2023, pp. 15, 43–45
GRI 401: Employment 2016	401-1 New employee hires and employee turnover	Sustainability Report 2023, p. 40

GRI Content Index

GRI Standard	Disclosure	Location
Occupational Health and Safety		
GRI 3: Material Topics 2021	3-3 Management of material topics	Sustainability Report 2023, pp. 28, 39 Annual Report 2023, p. 45 Safety, Health and Environment (SHE) Standard
GRI 403: Occupational Health and Safety 2018	403-1 Occupational health and safety management system	Sustainability Report 2023, p. 28
	403-2 Hazard identification, risk assessment, and incident investigation	Sustainability Report 2023, p. 28
	403-3 Occupational health services	Sustainability Report 2023, p. 28
	403-4 Worker participation, consultation, and communication on occupational health and safety	Sustainability Report 2023, p. 28
	403-5 Worker training on occupational health and safety	Sustainability Report 2023, p. 28
	403-6 Promotion of worker health	Sustainability Report 2023, p. 28
	403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	Sustainability Report 2023, p. 28
	403-8 Workers covered by an occupational health and safety management system	Sustainability Report 2023, p. 28
	403-9 Work-related injuries	Sustainability Report 2023, p. 39
	403-10 Work-related ill health	Sustainability Report 2023, p. 39
Training and Education		
GRI 3: Material Topics 2021	3-3 Management of material topics	Annual Report 2023, pp. 43–45
GRI 404: Training and Education 2016	404-1 Average hours of training per year per employee	Annual Report 2023, p. 44, Sustainability Report 2023, p. 40
	404-2 Programmes for upgrading employee skills and transition assistance programmes	Annual Report 2023, p. 44, Sustainability Report 2023, p. 40
	404-3 Percentage of employees receiving regular performance and career development reviews	Sustainability Report 2023, p. 40

GRI Content Index

GRI Standard	Disclosure	Location
Diversity and Equal Opportunity		
GRI 3: Material Topics 2021	3-3 Management of material topics	Sustainability Report 2023, pp. 27, 39 Annual Report 2023, pp. 44–45
GRI 405: Diversity and Equal Opportunity 2016	405-1 Diversity of governance bodies and employees	Sustainability Report 2023, p. 39
Supplier Social Assessment		
GRI 3: Material Topics 2021	3-3 Management of material topics	Sustainability Report 2023, pp. 25 -26, 27, 38 Annual Report 2023, p. 40 Expectations of Third Parties Sustainability Partner Guide and Framework
GRI 414: Supplier Social Assessment 2016	414-2 Negative social impacts in the supply chain and actions taken	Sustainability Report 2023, p. 38 Modern Slavery Act Statement Human Rights Statement



Site certifications

June 2023

74%

Share of R&D and Operations sites with environmental certification (ISO 14001, ISO 50001, My Green Lab or Wildlife Habitat).

9%

Share of sites with sustainable building certifications (LEED, BREEM or WELL).

5%

Share of R&D and Operations sites with certified occupational health and safety management systems (ISO 45001).